This project will be a multicentre retrospective study of patients with relapsed/ refractory Diffuse Large B- Cell Lymphoma treated with at least two prior lines of systemic therapy that meet the inclusions criteria of the SADAL trial.

This study aims to describe the clinical outcomes of patient with refractory/ relapsed DLBCL in a contemporary Australian tertiary setting.

20 July 2023 – data collection at SCGH, Townsville NZ complete. Waiting for 3 sites

24 November 2023 – Data in from 3 sites, DTA executed. Around 100 patients

29 February 2024 – hope to start cleansing data soon. Target BLOOD 24

19 August 2024 – Data collected.

16 January 2025 – Aiming for abstract and manuscript end of Feb

19 February 2026 – Hope to circulate manuscript shortly